Gleostine

Risk of delayed and cumulative myelosuppression leading to fatal infections and bleeding. Monitor CBCs weekly for at least 6 weeks after each dose; withhold each subsequent dose for >6 weeks if needed until platelets recover to ≥100,000/mm³ and leukocytes to ≥4000/mm³. Risk of overdosage (fatal toxicity); prescribe only 1 dose for every 6-week cycle. Monitor liver and renal function. Perform pulmonary function tests prior to and frequently during therapy; increased risk of pulmonary toxicity in patients with baseline <70% of the predicted Forced Vital Capacity or Carbon Monoxide Diffusing Capacity; permanently discontinue if pulmonary fibrosis occurs. Pregnancy. Use adequate contraception during therapy and for 2 weeks (females) or 3.5 months (males with female partners) after final dose. Nursing mothers: not recommended (during therapy and for 2 weeks after final dose).

Risk of delayed and cumulative myelosuppression leading to fatal infections and bleeding. Monitor CBCs weekly for at least 6 weeks after each dose; withhold each subsequent dose for >6 weeks if needed until platelets recover to ≥100,000/mm³ and leukocytes to ≥4000/mm³. Risk of overdosage (fatal toxicity); prescribe only 1 dose for every 6-week cycle. Monitor liver and renal function. Perform pulmonary function tests prior to and frequently during therapy; increased risk of pulmonary toxicity in patients with baseline <70% of the predicted Forced Vital Capacity or Carbon Monoxide Diffusing Capacity; permanently discontinue if pulmonary fibrosis occurs. Pregnancy. Use adequate contraception during therapy and for 2 weeks (females) or 3.5 months (males with female partners) after final dose. Nursing mothers: not recommended (during therapy and for 2 weeks after final dose).